Tanja Dujic1,2, Kaixin Zhou2, Roger Tavendale2, Colin N A Palmer2, Ewan R Pearson3. 1. Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina. 2. Division of Molecular & Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland, U.K. 3. Division of Molecular & Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland, U.K. e.z.pearson@dundee.ac.uk.
Abstract
OBJECTIVE: The mechanism causing gastrointestinal intolerance to metformin treatment is unknown. We have previously shown that reduced-function alleles of organic cation transporter 1 (OCT1) are associated with increased intolerance to metformin. Considering recent findings that serotonin reuptake transporter (SERT) might also be involved in metformin intestinal absorption, and the role of serotonin in gastrointestinal physiology, in this study we investigated the association between a common polymorphism in the SERT gene and metformin gastrointestinal intolerance. RESEARCH DESIGN AND METHODS: We explored the effect of composite SERT 5-HTTLPR/rs25531 genotypes, L*L* (LALA), L*S* (LALG, LAS), and S*S* (SS, SLG, LGLG), in 1,356 fully tolerant and 164 extreme metformin-intolerant patients by using a logistic regression model, adjusted for age, sex, weight, OCT1 genotype, and concomitant use of medications known to inhibit OCT1 activity. RESULTS: The number of low-expressing SERT S* alleles increased the odds of metformin intolerance (odds ratio [OR] 1.31 [95% CI 1.02-1.67], P = 0.031). Moreover, a multiplicative interaction between the OCT1 and SERT genotypes was observed (P = 0.003). In the analyses stratified by SERT genotype, the presence of two deficient OCT1 alleles was associated with more than a ninefold higher odds of metformin intolerance in patients carrying the L*L* genotype (OR 9.25 [95% CI 3.18-27.0], P < 10-4); however, it showed a much smaller effect in L*S* carriers and no effect in S*S* carriers. CONCLUSIONS: Our results indicate that the interaction between OCT1 and SERT genes might play an important role in metformin intolerance. Further studies are needed to replicate these findings and to substantiate the hypothesis that metformin gastrointestinal side effects could be related to the reduced intestinal serotonin uptake.
OBJECTIVE: The mechanism causing gastrointestinal intolerance to metformin treatment is unknown. We have previously shown that reduced-function alleles of organic cation transporter 1 (OCT1) are associated with increased intolerance to metformin. Considering recent findings that serotonin reuptake transporter (SERT) might also be involved in metformin intestinal absorption, and the role of serotonin in gastrointestinal physiology, in this study we investigated the association between a common polymorphism in the SERT gene and metformingastrointestinal intolerance. RESEARCH DESIGN AND METHODS: We explored the effect of composite SERT5-HTTLPR/rs25531 genotypes, L*L* (LALA), L*S* (LALG, LAS), and S*S* (SS, SLG, LGLG), in 1,356 fully tolerant and 164 extreme metformin-intolerant patients by using a logistic regression model, adjusted for age, sex, weight, OCT1 genotype, and concomitant use of medications known to inhibit OCT1 activity. RESULTS: The number of low-expressing SERT S* alleles increased the odds of metformin intolerance (odds ratio [OR] 1.31 [95% CI 1.02-1.67], P = 0.031). Moreover, a multiplicative interaction between the OCT1 and SERT genotypes was observed (P = 0.003). In the analyses stratified by SERT genotype, the presence of two deficient OCT1 alleles was associated with more than a ninefold higher odds of metformin intolerance in patients carrying the L*L* genotype (OR 9.25 [95% CI 3.18-27.0], P < 10-4); however, it showed a much smaller effect in L*S* carriers and no effect in S*S* carriers. CONCLUSIONS: Our results indicate that the interaction between OCT1 and SERT genes might play an important role in metformin intolerance. Further studies are needed to replicate these findings and to substantiate the hypothesis that metformin gastrointestinal side effects could be related to the reduced intestinal serotonin uptake.
Authors: Yvonne Meier; Jyrki J Eloranta; Jutta Darimont; Manfred G Ismair; Christian Hiller; Michael Fried; Gerd A Kullak-Ublick; Stephan R Vavricka Journal: Drug Metab Dispos Date: 2007-01-12 Impact factor: 3.922
Authors: Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman Journal: Am J Hum Genet Date: 2006-03-28 Impact factor: 11.025
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2015-01 Impact factor: 19.112
Authors: Tanja Dujic; Kaixin Zhou; Louise A Donnelly; Roger Tavendale; Colin N A Palmer; Ewan R Pearson Journal: Diabetes Date: 2014-12-15 Impact factor: 9.461
Authors: Emilie Bahne; Emily W L Sun; Richard L Young; Morten Hansen; David P Sonne; Jakob S Hansen; Ulrich Rohde; Alice P Liou; Margaret L Jackson; Dayan de Fontgalland; Philippa Rabbitt; Paul Hollington; Luigi Sposato; Steven Due; David A Wattchow; Jens F Rehfeld; Jens J Holst; Damien J Keating; Tina Vilsbøll; Filip K Knop Journal: JCI Insight Date: 2018-12-06
Authors: Alexey V Zilov; Sulaf Ibrahim Abdelaziz; Afaf AlShammary; Ali Al Zahrani; Ashraf Amir; Samir Helmy Assaad Khalil; Kerstin Brand; Nabil Elkafrawy; Ahmed A K Hassoun; Adel Jahed; Nadim Jarrah; Sanaa Mrabeti; Imran Paruk Journal: Diabetes Metab Res Rev Date: 2019-07-24 Impact factor: 4.876
Authors: Laura J McCreight; Tore B Stage; Paul Connelly; Mike Lonergan; Flemming Nielsen; Cornelia Prehn; Jerzy Adamski; Kim Brøsen; Ewan R Pearson Journal: Diabetes Obes Metab Date: 2018-03-23 Impact factor: 6.577
Authors: Eva Rye Rasmussen; Pär Hallberg; Ekaterina V Baranova; Niclas Eriksson; Malgorzata Karawajczyk; Caroline Johansson; Marco Cavalli; Cyrielle Maroteau; Abirami Veluchamy; Gunilla Islander; Svante Hugosson; Ingrid Terreehorst; Folkert W Asselbergs; Pia Norling; Hans-Erik Johansson; Hugo Kohnke; Ann-Christine Syvänen; Moneeza K Siddiqui; Chim C Lang; Patrik K E Magnusson; Qun-Ying Yue; Claes Wadelius; Christian von Buchwald; Anette Bygum; Ana Alfirevic; Anke H Maitland-van der Zee; Colin N A Palmer; Mia Wadelius Journal: Pharmacogenomics J Date: 2020-02-21 Impact factor: 3.550